首页> 外文期刊>Italian Journal of Medicine >Biomarkers for sepsis: past, present and future
【24h】

Biomarkers for sepsis: past, present and future

机译:败血症的生物标志物:过去,现在和将来

获取原文
           

摘要

Sepsis is a complication of severe infection associated with high mortality and open diagnostic issues. Treatment strategies are currently limited and essentially based on prompt recognition, aggressive supportive care and early antibiotic treatment. In the last years, extensive antibiotic use has led to selection, propagation and maintenance of drug-resistant microorganisms. In this context, several biomarkers have been proposed for early identification, etiological definition, risk stratification and improving antibiotic stewardship in septic patient care. Among these molecules, only a few have been translated into clinical practice. In this review, we provided an updated overview of established and developing biomarkers for sepsis, focusing our attention on their pathophysiological profile, advantages, limitations, and appropriate evidence-based use in the management of septic patients.
机译:败血症是与高死亡率和开放诊断问题有关的严重感染的并发症。当前的治疗策略是有限的,并且主要基于迅速识别,积极的支持治疗和早期抗生素治疗。近年来,广泛使用抗生素已导致对耐药微生物的选择,繁殖和维持。在这种情况下,已经提出了几种生物标记物,用于脓毒症患者护理中的早期识别,病因定义,风险分层和改善抗生素管理。在这些分子中,只有少数已经转化为临床实践。在这篇综述中,我们提供了脓毒症已建立和发展中生物标志物的最新概况,将我们的注意力集中在脓毒症患者的病理生理特征,优势,局限性以及基于证据的适当使用上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号